Mezigdomide not checked
Celgene · BMS-986348 · CC-92480
FollowEvery change as it happens, and a Monday email
Trials
10 active
17 in total · 10 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Multiple Myeloma (5 trials), Relapsed or Refractory Multiple Myeloma (2 trials)
- Main trialPhase 3
- “The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.”In the company’s words, NCT05552976 on ClinicalTrials.gov
- Other names
- BMS-986348 · CC-92480
Other drugs for Multiple Myeloma
- Anitocabtagene-autoleucelGilead (Kite) · Phase 3
- CM336Keymed Biosciences Co.Ltd · Phase 3
- IBI3003Innovent · Phase 3
- PomalidomideCelgene · Phase 3
- CevostamabRoche · Phase 3
- DaratumumabJanssen Research & Development, LLC · Phase 3
Coming up5
- 30 NovPhase 1/2 trial completes · ClinicalTrials.gov
- 10 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- Apr 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 31 May 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 1 Aug 2028Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials17
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 28 Sep 2026 | A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2) | |
| Phase 3Recruiting | 10 Jan 2027 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | |
| Phase 1/2Recruiting | 12 Oct 2026 | A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma | |
| Phase 1/2Active, not recruiting | 30 Nov 2026 | A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) | |
| Phase 1/2Recruiting | Apr 2027 | Selinexor and Backbone Treatments of Multiple Myeloma Patients | |
| Phase 1/2Recruiting | 31 May 2027 | A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 1Recruiting | 1 Aug 2028 | A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 1/2Terminated | 20 Aug 2025 | A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) | |
| Phase 1Completed | 13 May 2021 | A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants | |
| Phase 1Completed | 8 Oct 2021 | A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants | |
| Phase 1Completed | 12 Nov 2022 | A Study to Assess the Drug Levels of CC-92480 After Coadministration With Rifampin and Itraconazole, and the Drug Levels of Digoxin and Rosuvastatin After Coadministration With CC-92480 in Healthy Participants | |
| Phase 1Completed | 13 Sep 2023 | A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment | |
| Phase 1Completed | 15 Nov 2024 | A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment | |
| Phase 1Terminated | 3 Jun 2025 | A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma | |
| Phase 2Authorised | not given | A multicenter phase 2 study of Belantamab mafodotin and Mezigdomide in combination with a phase Ib Safety run in patients with relapsed multiple myeloma following BCMA-targeting CAR-T cells or bispecific antibodies. The IFM 2024-01 clinical trial (BELAMI) | |
| Phase 2Authorised | not given | A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM). (MEZI-KD) | |
| Phase 2Authorised | not given | Multicenter, open label, phase II clinical trial evaluating the combination of elranatamab with mezigdomide and dexamethasone in patients with relapsed/refractory multiple myeloma |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026